CN100355419C - 治疗膀胱过度活动的药物 - Google Patents

治疗膀胱过度活动的药物 Download PDF

Info

Publication number
CN100355419C
CN100355419C CNB038131498A CN03813149A CN100355419C CN 100355419 C CN100355419 C CN 100355419C CN B038131498 A CNB038131498 A CN B038131498A CN 03813149 A CN03813149 A CN 03813149A CN 100355419 C CN100355419 C CN 100355419C
Authority
CN
China
Prior art keywords
effect
overactive bladder
tamsulosin
bladder
urinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038131498A
Other languages
English (en)
Chinese (zh)
Other versions
CN1658859A (zh
Inventor
R·冯梅斯特恩
N·J·维瑟
梶井宽
滝口啓行
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Astellas Pharma Inc
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Yamanouchi Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of CN1658859A publication Critical patent/CN1658859A/zh
Application granted granted Critical
Publication of CN100355419C publication Critical patent/CN100355419C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038131498A 2002-06-07 2003-06-05 治疗膀胱过度活动的药物 Expired - Fee Related CN100355419C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP166408/2002 2002-06-07
JP2002166408 2002-06-07

Publications (2)

Publication Number Publication Date
CN1658859A CN1658859A (zh) 2005-08-24
CN100355419C true CN100355419C (zh) 2007-12-19

Family

ID=29727628

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038131498A Expired - Fee Related CN100355419C (zh) 2002-06-07 2003-06-05 治疗膀胱过度活动的药物

Country Status (16)

Country Link
US (2) US20060035923A1 (de)
EP (1) EP1552825A4 (de)
JP (1) JP4466370B2 (de)
KR (1) KR20050008795A (de)
CN (1) CN100355419C (de)
AR (1) AR040248A1 (de)
AU (1) AU2003242166A1 (de)
BR (1) BR0311414A (de)
CA (1) CA2487899A1 (de)
IL (1) IL165370A0 (de)
MX (1) MXPA04012070A (de)
NO (1) NO20050060L (de)
PL (1) PL372560A1 (de)
RU (1) RU2004135563A (de)
TW (1) TW200408387A (de)
WO (1) WO2003103659A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
ZA200608614B (en) * 2004-03-25 2008-06-25 Astellas Pharma Inc Composition for solid pharmaceutical preparation of solifenacin or salt thereof
KR101836467B1 (ko) * 2004-03-25 2018-03-08 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
BRPI0519270A2 (pt) * 2004-12-27 2009-01-06 Astellas Pharma Inc composiÇço farmacÊutica particulada estÁvel de solifenacina ou um sal
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
EP2172201A4 (de) * 2007-07-20 2011-07-06 Astellas Pharma Inc Pharmazeutische zusammensetzung zur linderung von symptomen der unteren harnwege im zusammenhang mit prostatomegalie
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
EP2223690A4 (de) * 2007-12-21 2011-02-23 Astellas Pharma Inc Pharmazeutische zusammensetzung zur linderung von symptomen der unteren harnwege
EP2181707A1 (de) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Kombinierte Verwendung eines alpha-adrenergischen Rezeptorantagonisten und eines Antimuskarinmittels
MY160652A (en) * 2009-02-04 2017-03-15 Astellas Pharma Inc Pharmaceutical composition for oral administration
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
KR102027912B1 (ko) * 2011-02-15 2019-10-02 지엘팜텍주식회사 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제
CN107157991A (zh) * 2012-03-19 2017-09-15 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
CN102743757A (zh) * 2012-07-09 2012-10-24 张家华 治疗膀胱流出道梗阻所致膀胱活动过度的药物
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN106265667B (zh) * 2015-05-18 2019-01-25 中国科学院生物物理研究所 一种氯喹的用途
CN106562968B (zh) * 2015-10-13 2019-08-13 南京华威医药科技集团有限公司 包含盐酸坦洛辛和琥珀酸索利那新的药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
AU2021265311A1 (en) * 2020-04-27 2022-12-08 Zim Laboratories Limited Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447958A (en) * 1980-02-08 1995-09-05 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives, their preparation, and pharmaceutical compositions, containing them
CN1346268A (zh) * 1999-08-09 2002-04-24 山之内制药株式会社 下部尿路症治疗用医药组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447958A (en) * 1980-02-08 1995-09-05 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives, their preparation, and pharmaceutical compositions, containing them
CN1346268A (zh) * 1999-08-09 2002-04-24 山之内制药株式会社 下部尿路症治疗用医药组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
lower urinary tract symptoms:what are the implications for thepatients. Roberto M Scarpa.Eur Urol,Vol.40 No.suppl. 2001 *
protential therapeutic targets for treatment of theoveractivebladder.Donna J Urol.world J Urol,Vol.19. 2001 *
治疗膀胱过度活动症的新药托特罗定 袁宁.药学进展，第25卷第1期 2001 *

Also Published As

Publication number Publication date
IL165370A0 (en) 2006-01-15
EP1552825A1 (de) 2005-07-13
JP4466370B2 (ja) 2010-05-26
MXPA04012070A (es) 2005-03-07
CN1658859A (zh) 2005-08-24
US20070270459A1 (en) 2007-11-22
CA2487899A1 (en) 2003-12-18
AU2003242166A1 (en) 2003-12-22
KR20050008795A (ko) 2005-01-21
WO2003103659A1 (ja) 2003-12-18
TW200408387A (en) 2004-06-01
NO20050060L (no) 2005-03-04
US20060035923A1 (en) 2006-02-16
BR0311414A (pt) 2005-03-15
RU2004135563A (ru) 2005-06-10
EP1552825A4 (de) 2009-11-25
JPWO2003103659A1 (ja) 2005-10-06
AR040248A1 (es) 2005-03-23
PL372560A1 (en) 2005-07-25

Similar Documents

Publication Publication Date Title
CN100355419C (zh) 治疗膀胱过度活动的药物
US20220152053A1 (en) Methods and compositions for treating various disorders
US7084116B2 (en) Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators
CN102939008A (zh) 改善睡眠质量的方法
CN1211081C (zh) 坦洛新在制备神经原性膀胱伴有的排尿障碍治疗剂上的应用
WO2002062390A1 (en) Medicinal compositions for treating lower uropathy
JP2006511624A (ja) α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
UA79238C2 (en) Use of derivatives of aryl (or heteroaryl) azolylcarbinoles
JP2005516977A (ja) 尿失禁の処置での４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ（２，３−ｄ−ピリミジン）の使用
TW567068B (en) Medicinal compositions for treating lower uropathy
JP2001114679A (ja) 下部尿路症治療剤
JP6031722B2 (ja) 女性の排尿障害の治療剤
KR100965205B1 (ko) 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제
HK1078012A (en) Therapeutic agent for overactive bladder
JPWO2005007155A1 (ja) 医薬組成物
JP2000080032A (ja) 排出障害治療剤
MXPA05002460A (es) Agente terapeutico de liberacion de dolor h ipogastrico y/o perineal.
JPWO2000000187A1 (ja) 排出障害治療用医薬組成物
JPWO2001010436A1 (ja) 下部尿路症治療用医薬組成物
Times Optometry Times Chief Optometric Editor Ernie Bowling, OD, FA AO, hopes prescrip
TW201043610A (en) Methods of treating bladder dysfunction using netupitant
NZ543762A (en) Use of an alpha2delta subunit calcium channel modulator such as gabapentin or pregabalin in a medicament for treating non-painful disorders of the bladder

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071219

Termination date: 20100605